Quote:

---

Since cancer.gov defines cancer as "a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body" -

and since leronlimab's MOA interrupts the CCR5 link (among other things) that allows cancer cells to propagate -

then how come leronlimab seems to be viable against some cancers, but not all?

In other words, if cancer is cancer, then how come leronlimab's MOA isn't a silver bullet - silver M61 Vulcan cannon - against all cancers?

---

CCR5 does not express on all types of cells of the body. Tumors that originate from cells that do express CCR5 are going to be high on the list of cancers treatable by leronlimab. Any cancers that go metastatic will also be high up on that list since CCL5 directs a transport mechanism for those cells. Even outside those two instances leronlimab can treat many forms of cancers. How they rank will be dependent upon the extent that they hijack the immune system to protect themselves. The greater the use of CCR5 in immune cells by the tumor, the more leronlimab can help.

There is a nice bar chart that shows the levels of CCR5 expressed in various cancers. I saved a copy to my computer but I can't find it. I searched online but haven't been able to track it down yet. No, it's not Patterson's one. He used a very small sample size and it skews, sometimes dramatically, from what other doctors have seen.